title: Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men.
abstract: The neuropeptide Y (NPY) is a neuropeptide with a role in the regulation of satiety and energy balance of body weight, insulin release, cardiovascular and central endocrine systems. In order to evaluate whether the NPY gene variations contribute to development of type 2 diabetes (T2DM), we have performed a genetic association study for Leu7Pro (T1128 C) polymorphism of the NPY gene in impaired glucose tolerance (IGT) and T2DM. Genotyping experiments for this non-synonymous single nucleotide polymorphism (SNP) in 263 patients with T2DM, 309 subjects with IGT and 469 non-diabetic healthy individuals in Swedish Caucasians were performed by using Dynamic Allele Specific Hybridisation (DASH). We found that the frequencies of the "risk" allele C in the subjects with IGT and the patients with T2DM in Swedish men were 13 % (p = 0.002, OR = 3.70, 1.65 - 8.29 95 % CI) and 10 % (p = 0.007, OR = 4.80, 1.47 - 11.33 95 % CI) respectively, which were significantly higher than the C allele frequency in non-diabetic controls (6 %). Furthermore, we found that the carriers with TC and CC genotypes in the subjects with IGT in Swedish men had significantly higher fasting plasma glucose in comparison with the TT carriers (5.6 +/- 0.7 mmol/l vs. 5.2 +/- 0.7 mmol/l, p = 0.021). The present study thus provides the evidence that Leu7Pro polymorphism in the NPY gene is associated with IGT and T2DM in Swedish men, and indicates that the NPY gene variations contribute to development of T2DM. Questions of gender specificity may be explained by genetic backgrounds, sense of coherence for stress and other factors in environment.
authors.affiliation: Diabetes Center Karolinska, Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Nordman
authors.forename: B
authors.initials: B
authors.lastname: Ding
authors.forename: C-G
authors.initials: CG
authors.lastname: Ostenson
authors.forename: L
authors.initials: L
authors.lastname: Kärvestedt
authors.forename: K
authors.initials: K
authors.lastname: Brismar
authors.forename: S
authors.initials: S
authors.lastname: Efendic
authors.forename: H F
authors.initials: HF
authors.lastname: Gu
mesh_terms: D000328:Adult; D000483:Alleles; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics*; D005215:Fasting; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D018149:Glucose Intolerance / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D007328:Insulin / Q000097:blood; D007930:Leucine / Q000031:analogs & derivatives* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000235:genetics*; D016017:Odds Ratio; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics*; D011392:Proline / Q000235:genetics*; D012727:Sex Characteristics; D013548:Sweden
chemical_list: D001786:Blood Glucose; D007328:Insulin; D009478:Neuropeptide Y; C035766:leucinal; D011392:Proline; D007930:Leucine